1-3 of 3
Michael S.Y. Low
Close
Sort by
Journal Articles

Carfilzomib Use Among Patients with Relapsed/Refractory Multiple Myeloma in the Asia Pacific Region: Characteristics and Outcomes By Regimen from a Prospective, Real-World Study

Hang Quach, Sung-Soo Yoon, Kihyun Kim, Ji Hyun Lee, Chandramouli Nagarajan, Phoebe Joy Ho, Michael S.Y. Low, Wei-Han Huang, Raymond Wong, Nina Liao, ChingFeng Lin, Matthew Britland, Julia Li, Stella Chai, Jin Seok Kim
Journal: Blood
Blood (2022) 140 (Supplement 1): 4264–4266.
https://doi.org/10.1182/blood-2022-159324
Published: 2022
Journal Articles

Inferior Outcomes for Multiple Myeloma (MM) Patients (pts) Harbouring t(11;14) and the Promise of Venetoclax, Real-World Australian Retrospective

Kenneth JC Lim, Dipti Talaulikar, Joanne L C Tan, Joanna Loh, Pratheepan Puvanakumar, James Anton Kuzich, Michelle Ho, Matthew Murphy, Nicole Zeglinas, Sue Morgan, Michael S.Y. Low, David Routledge, Andrew B M Lim, Simon D. Gibbs, Slavisa Ninkovic
Journal: Blood
Blood (2021) 138 (Supplement 1): 4752.
https://doi.org/10.1182/blood-2021-145508
Published: 2021
Journal Articles

Loss of IRF4 Results in Multiple Myeloma Cell Apoptosis through the Transcriptional up-Regulation of the BH3-Only Proteins Bmf and BIM

Pasquale L. Fedele, MBBS PhDFRACP FRCPA, Yang Liao, PhD, Jianan Gong, PhD, Mark van Delft, PhD, Michael S.Y. Low, MBBS PhDFRACP FRCPA, Lin Tai, PhD, Marco J Herold, PhD, Julie Tellier, PhD, George Grigoriadis, MBBS PhDFRACP FRCPA, David C.S. Huang, MBBS MRCP PhD, Wei Shi, PhD, Stephen Nutt, PhD, Simon Willis, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3103.
https://doi.org/10.1182/blood-2019-126417
Published: 2019